Skip to main content
  • Targeted intra-arterial anti-VEGF therapy for medically refractory radiation-induced necrosis in the brain

    Final Number:

    Shervin R. Dashti MD PhD; Aaron Spalding MD, PhD; Robert J Kadner MD; Tom L. Yao MD; David A. Sun MD, PhD; Arooshi Kumar BS; Renato V LaRocca

    Study Design:

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2014 Annual Meeting

    Introduction: Radiation necrosis (RN) is a serious complication that can occur in up to 10% of brain radiotherapy cases, with the incidence dependent on both dose and brain location. Available medical treatment for RN includes steroids, vitamin E, pentoxiphylline, and hyperbaric oxygen. A significant number of patients however, are medically refractory and experience progressive neurological decline, disabling headaches, and decreased quality of life. Vascular endothelial growth factor (VEGF) is a known mediator of cerebral edema in radiation necrosis. Recent reports have shown successful treatment of RN with intravenous bevacizumab, a monoclonal antibody for VEGF. Bevacizumab however, is associated with significant systemic complications including venous thrombosis, pulmonary embolus, GI perforation, wound dehiscence, and severe hypertension. We hypothesize that using lower drug doses would lower systemic exposure and decrease complication rates. By using intra-arterial route of drug administration following blood-brain-barrier disruption (BBBD), we aim to lower the bevacizumab dose while increasing target delivery.

    Methods: Herein, we present two pediatric patients with cerebral arteriovenous malformations, who presented with medically intractable RN following stereotactic radiosurgery. They received a single intra-arterial infusion of 2.5 mg/kg bevacizumab after hyperosmotic BBBD.

    Results: At mean follow-up period of 6-months, the patients experienced significant and durable clinical and radiographic response: Both patients experienced resolution of their previously intractable headaches as well as reversal of cushingoid features as they were successfully weaned off steroids. One patient regained significant motor strength. There was an associated greater than 70% reduction in cerebral edema.

    Conclusions: Intra-arterial administration of a single low dose of bevacizumab after blood brain barrier disruption was safe, and resulted in durable clinical and radiographic improvement at concentrations well below the typical systemic intravenous route. Advantages over intravenous route may include higher concentration of drug delivery to the affected brain, decreased systemic toxicity, as well as significantly lower cost.

    Patient Care: We have shown that intra-arterial bevacizumab after hyperosmotic blood brain barrier breakdown appears to be safe and effective treatment for medically refractory radiation necrosis in the brain. Advantages over intravenous route may include higher concentration of drug delivery to the target brain tissue, decreased systemic toxicity because of the much smaller dose of bevacizumab used, as well as significantly lower cost.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1) Understand the role of anti-VEGF (bevacizumab) therapy for medically refractory radiation necrosis. 2) Discuss known serious systemic complications of intravenous bevacizumab treatment. 3) Discuss the use of intra-arterial bevacizumab delivery following blood-brain-barrier breakdown to maintain drug efficacy while markedly reducing systemic exposure and potential toxicity. 4) Understand technical considerations for intra-arterial bevacizumab administration following blood-brain barrier breakdown.

    References: [1] Abbrederis K, Kremer M Schuhmacher C. [ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery]. Chirurg 2008;79:351-355. [2] Armstrong BK, Robinson PJ Rapoport SI. Size-dependent blood-brain barrier opening demonstrated with [14c]sucrose and a 200,000-da [3h]dextran. Exp Neurol 1987;97:686-696. [3] Boockvar JA, Tsiouris AJ, Hofstetter CP, et al. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. J Neurosurg. [4] Bullard DE Bigner DD. Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumors. J Neurosurg 1985;63:2-16. [5] Burkhardt JK, Shin BJ, Schlaff CD, et al. Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme. Journal of experimental therapeutics & oncology 2011;9:183-186. [6] Chamberlain MC Johnston S. Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol 2009;91:359-367. [7] Deibert CP, Ahluwalia MS, Sheehan JP, et al. Bevacizumab for refractory adverse radiation effects after stereotactic radiosurgery. Journal of neuro-oncology 2013;115:217-223. [8] Epenetos AA, Courtenay-Luck N, Pickering D, et al. Antibody guided irradiation of brain glioma by arterial infusion of radioactive monoclonal antibody against epidermal growth factor receptor and blood group a antigen. Br Med J (Clin Res Ed) 1985;290:1463-1466. [9] Flickinger JC, Kondziolka D, Lunsford LD, et al. Development of a model to predict permanent symptomatic postradiosurgery injury for arteriovenous malformation patients. Arteriovenous malformation radiosurgery study group. Int J Radiat Oncol Biol Phys 2000;46:1143-1148. [10] Gobin YP, Cloughesy TF, Chow KL, et al. Intraarterial chemotherapy for brain tumors by using a spatial dose fractionation algorithm and pulsatile delivery. Radiology 2001;218:724-732. [11] Grivas AA, Trafalis DT Athanassiou AE. Implication of bevacizumab in fatal arterial thromboembolic incidents. J BUON 2009;14:115-117. [12] Heinzerling JH Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: Incidence, etiology, and management. Curr Surg 2006;63:334-337. [13] Lee YS, Bullard DE, Zalutsky MR, et al. Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131i-radiolabeled murine monoclonal antibody in a human glioma xenograft model. Cancer Res 1988;48:559-566. [14] Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. International Journal of radiation Oncology, Biology, Physics 2011;79:1487-1495. [15] Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011;79:1487-1495. [16] Monaco EA, 3rd, Niranjan A, Kano H, et al. Management of adverse radiation effects after radiosurgery for arteriovenous malformations. Progress in neurological surgery 2013;27:107-118. [17] Namba H, Kobayashi S, Iwadate Y, et al. Assessment of the brain areas perfused by superselective intra-arterial chemotherapy using single photon emission computed tomography with technetium-99m-hexamethyl-propyleneamine oxime--technical note. Neurol Med Chir (Tokyo) 1994;34:832-835. [18] Neuwelt EA, Barnett PA, Hellstrom KE, et al. Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. J Nucl Med 1994;35:1831-1841. [19] Neuwelt EA, Frenkel EP, D'Agostino AN, et al. Growth of human lung tumor in the brain of the nude rat as a model to evaluate antitumor agent delivery across the blood-brain barrier. Cancer Res 1985;45:2827-2833. [20] Nonoguchi N, Miyatake S, Fukumoto M, et al. The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: Pathological consideration of their potential roles. Journal of neuro-oncology 2011;105:423-431. [21] Sadraei NH, Dahiya S, Chao ST, et al. Treatment of cerebral radiation necrosis with bevacizumab: The cleveland clinic experience. American journal of clinical oncology 2013. [22] Suenaga M, Mizunuma N, Kobayashi K, et al. Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab. Med Oncol;27:807-814. [23] Takano M, Kikuchi Y, Kato M, et al. Bowel perforation associated with bevacizumab therapy in recurrent ovarian cancers without bowel obstruction or bowel involvement]. Gan To Kagaku Ryoho 2008;35:1981-1984. [24] Vredenburgh JJ, Desjardins A, Kirkpatrick JP, et al. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. [25] Williamson R, Kondziolka D, Kanaan H, et al. Adverse radiation effects after radiosurgery may benefit from oral vitamin e and pentoxifylline therapy: A pilot study. Stereotactic and functional neurosurgery 2008;86:359-366. [26] Zalutsky MR, Moseley RP, Benjamin JC, et al. Monoclonal antibody and f(ab')2 fragment delivery to tumor in patients with glioma: Comparison of intracarotid and intravenous administration. Cancer Res 1990;50:4105-4110. [27] Zalutsky MR, Moseley RP, Coakham HB, et al. Pharmacokinetics and tumor localization of 131i-labeled anti-tenascin monoclonal antibody 81c6 in patients with gliomas and other intracranial malignancies. Cancer Res 1989;49:2807-2813. [28] Ziylan YZ, Robinson PJ Rapoport SI. Differential blood-brain barrier permeabilities to [14c]sucrose and [3h]inulin after osmotic opening in the rat. Exp Neurol 1983;79:845-857.

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy